Protagonist Therapeutics Inc banner

Protagonist Therapeutics Inc
NASDAQ:PTGX

Watchlist Manager
Protagonist Therapeutics Inc Logo
Protagonist Therapeutics Inc
NASDAQ:PTGX
Watchlist
Price: 105.705 USD 0.22%
Market Cap: $6.7B

Protagonist Therapeutics Inc
Accounts Payable

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Protagonist Therapeutics Inc
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
Protagonist Therapeutics Inc
NASDAQ:PTGX
Accounts Payable
$5.3m
CAGR 3-Years
14%
CAGR 5-Years
11%
CAGR 10-Years
15%
Abbvie Inc
NYSE:ABBV
Accounts Payable
$34.7B
CAGR 3-Years
11%
CAGR 5-Years
11%
CAGR 10-Years
23%
Gilead Sciences Inc
NASDAQ:GILD
Accounts Payable
$715m
CAGR 3-Years
-8%
CAGR 5-Years
-3%
CAGR 10-Years
-5%
Amgen Inc
NASDAQ:AMGN
Accounts Payable
$20.9B
CAGR 3-Years
137%
CAGR 5-Years
71%
CAGR 10-Years
36%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accounts Payable
$3.9B
CAGR 3-Years
134%
CAGR 5-Years
91%
CAGR 10-Years
48%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accounts Payable
$6.8B
CAGR 3-Years
126%
CAGR 5-Years
70%
CAGR 10-Years
47%
No Stocks Found

Protagonist Therapeutics Inc
Glance View

Market Cap
6.7B USD
Industry
Biotechnology

Protagonist Therapeutics Inc. stands as a pioneering player in the biopharmaceutical landscape, diligently orchestrating the journey from scientific discovery to therapeutic breakthroughs. Established with the vision to exploit the therapeutic potential of peptides, the company has carved a niche for itself by focusing on innovative peptide-based drug discovery and development. Their proprietary technology platform is designed to genetically engineer and optimize peptides aimed at treating a spectrum of diseases, notably in areas of unmet medical needs such as autoimmune conditions and rare genetic disorders. The fusion of cutting-edge biotechnology and seasoned expertise enables Protagonist to transform promising scientific concepts into viable medicines, paving the way for advancements in patient treatment options. Fueling its growth and revenue potential, Protagonist Therapeutics operates primarily through partnerships and collaborative alliances, as well as progressing its proprietary pipeline. By leveraging strategic collaborations with established pharmaceutical giants, the company garners funding, technological insights, and broader developmental capabilities. This collaborative synergy not only bolsters their research endeavors but also hastens the clinical development and eventual commercialization of their pipeline products. Their ability to secure partnerships and effectively progress their drug candidates through various clinical stages is critical to their financial model, converting scientific innovation into shareholder value and societal impact. The company continues to navigate the complexities of drug development with a steadfast focus on unlocking the therapeutic potential of peptides, aspiring to merge innovation with tangible health benefits.

PTGX Intrinsic Value
12.827 USD
Overvaluation 88%
Intrinsic Value
Price $105.705

See Also

What is Protagonist Therapeutics Inc's Accounts Payable?
Accounts Payable
5.3m USD

Based on the financial report for Dec 31, 2025, Protagonist Therapeutics Inc's Accounts Payable amounts to 5.3m USD.

What is Protagonist Therapeutics Inc's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
15%

Over the last year, the Accounts Payable growth was 231%. The average annual Accounts Payable growth rates for Protagonist Therapeutics Inc have been 14% over the past three years , 11% over the past five years , and 15% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett